China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

Rhea-AI Summary

China Pharma Holdings (NYSE American: CPHI) has announced a 1-for-10 reverse stock split effective April 15, 2025. The company's Board of Directors authorized a reverse split ratio between 1:10 and 1:20 on October 22, 2024, which was approved by stockholders on December 22, 2024. The Board ultimately fixed the ratio at 1:10 on March 26, 2025.

Under this arrangement, every 10 shares of CPHI's issued and outstanding common stock will be automatically converted into one share. The stock will continue trading on NYSE American under the symbol 'CPHI' with a new CUSIP number: 16941T 401. Any fractional shares resulting from the split will be rounded up to the next whole number, ensuring that stockholders' percentage interests remain unchanged except for minor adjustments due to fractional share treatment.

Positive

• Higher nominal share price could attract institutional investors
• Maintenance of NYSE American listing status

Negative

• Implementation of reverse stock split typically indicates previous stock price decline
• Potential risk of delisting concerns, as reverse splits are often used to maintain exchange listing requirements

News Market Reaction

-41.44%

1 alert

-41.44% News Effect

On the day this news was published, CPHI declined 41.44%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

HAIKOU, China, April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Tuesday, April 15, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T 401.

The reverse stock split at a ratio ranges between 1:10 and 1:20 was authorized by the Company's Board of Directors (the "Board") through unanimous written consent on October 22, 2024 and adopted by the Company's stockholders through the Annual Meeting for the fiscal year ended on December 31, 2023, which was held on December 22, 2024. The Board fixed a ratio of 1:10 on March 26, 2025.

Upon the effectiveness of the reverse stock split, every 10 shares of the Company's issued and outstanding common stock will automatically be converted into one share of issued and outstanding common stock. No fractional shares will be issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split will be rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's outstanding common stock, except for adjustments that may result from the treatment of fractional shares.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty pharmaceutical company that develops, manufactures, and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement 

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.

View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announces-1-for-10-reverse-stock-split-302421049.html

SOURCE China Pharma Holdings, Inc.

FAQ

When will China Pharma Holdings (CPHI) implement its reverse stock split?

CPHI will implement the 1-for-10 reverse stock split on April 15, 2025, with trading beginning on a split-adjusted basis at market open.

What happens to fractional shares in CPHI's reverse stock split?

Fractional shares resulting from the 1-for-10 split will be rounded up to the next whole number.

Will CPHI's reverse stock split affect shareholders' ownership percentage?

No, the reverse split will not alter stockholders' percentage interest in the company's outstanding common stock, except for minor adjustments from fractional shares.

What is the new CUSIP number for CPHI after the reverse split?

The new CUSIP number following the reverse stock split is 16941T 401.